Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal - Test2 - elhamkhani - TriplyDB

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal

http://www.wikidata.org/entity/Q28071657

about

Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants.The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old.

P2860

Q39456624-CCABE83F-32E9-46CA-98A0-6C24E65DB320 Q55100564-C0336860-6183-4183-9E2D-82F7AFD17F42

P2860

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal

http://www.wikidata.org/entity/Q28071657

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@ast

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@en

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@nl

type

label

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@ast

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@en

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@nl

prefLabel

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@ast

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@en

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@nl

P1433

Q28071657-E72B5CB0-E816-46DC-88D7-8E2BFC36E762

P1476

Q28071657-AB57713D-568F-4FDB-9434-DDCDD97A246D

P2093

Q28071657-0BA47C95-BBBF-41A1-86C6-B3EA3592E498

Q28071657-3B380A9E-E873-4DA3-9EDB-29F3350DC893

Q28071657-6EB611DB-1DDF-4D92-B621-C210AE046168

Q28071657-B5D4CA5F-8707-4F8B-B5F2-5A6DFDB71036

Q28071657-B8B0E28E-A757-4B2E-9759-1BBFA3986BE5

Q28071657-C7FC61AC-B75D-4150-AFD9-E6D0AD6DF3AE

P2860

Q28071657-022A5EF3-9939-40C6-B8ED-064F11EA4FC7

Q28071657-0651CBFF-8F50-4C7D-A842-AD12F68AA98D

Q28071657-0E5D0B72-C947-4968-8177-2B7C74287BEF

Q28071657-113A8978-46CF-4F19-8C2F-7F54AFCAA745

Q28071657-11D9972E-C11C-4E22-AC4F-6E670C81F991

Q28071657-13981AEE-609A-4DA7-8809-7D169F598DB4

Q28071657-16883494-ECD5-40DA-9A1C-47B0D4DCC0CF

Q28071657-178BD40A-A711-4695-AAD2-D825BF3B79F6

Q28071657-19A65BBA-BE35-4CFB-86DF-F43CEEDD050E

Q28071657-1BD80F64-7161-4FF0-B747-22A5A11B1269

P2888

Q28071657-AC104508-2D92-4086-AAD4-8200D31DBDB1

P304

Q28071657-41E3DB51-0A8D-4C6C-B162-E2E022E731A4

P31

Q28071657-290A896F-7C51-4DCB-B549-13C342B293DE

P3181

Q28071657-9805922D-9D8D-422F-B38B-280D5A74AC83

P356

Q28071657-ACCB5111-89B3-44AD-A4ED-5F0FAADC55AE

P407

Q28071657-80EDA4B0-0B15-4B27-8AAC-F3C556C45AB2

P433

Q28071657-65F75A23-2DE7-424A-B5E2-5D4FAC3F5900

P478

Q28071657-72E4FC2E-8272-4BAE-BE87-16D96529B808

P577

Q28071657-89644DDE-405B-4CF8-A1EC-0330400575B4

P6179

Q28071657-9A338E38-6647-42AD-92C8-65C5A3FC284A

P698

Q28071657-BDABE919-C60D-48EB-80D7-9A5C55E74DAB

P921

Q28071657-73C2EA61-4BD8-4603-A643-C940C918C9BC

P932

Q28071657-20723320-2E9C-48C5-824D-7317F016D2FD

P3181

P356

S13054-016-1422-2

P1433

P1476

Nonvitamin K antagonist oral a ...... es in measurement and reversal

@en

P2093

Hamim Zahir

http://www.w3.org/2001/XMLSchema#string

Hans J. Lanz

http://www.w3.org/2001/XMLSchema#string

Jerrold H. Levy

http://www.w3.org/2001/XMLSchema#string

Karen S. Brown

http://www.w3.org/2001/XMLSchema#string

Michael A. Grosso

http://www.w3.org/2001/XMLSchema#string

Michele F. Mercuri

http://www.w3.org/2001/XMLSchema#string

P2860

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Dabigatran versus warfarin in patients with atrial fibrillation

Idarucizumab for Dabigatran Reversal

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Oral rivaroxaban for symptomatic venous thromboembolism

Edoxaban versus warfarin in patients with atrial fibrillation

P2888

s13054-016-1422-2

P304

273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3370691

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S13054-016-1422-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1000676591

http://www.w3.org/2001/XMLSchema#string

P698

27659071

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

5034528

http://www.w3.org/2001/XMLSchema#string